The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Care of Patients with Spondyloarthritis

Care of Patients with Spondyloarthritis

December 9, 2021 • By Lara C. Pullen, PhD

  • Tweet
  • Email
Print-Friendly Version / Save PDF

ACR Convergence 2021—Alexis Ogdie, MD, associate professor of medicine and epidemiology at the University of Pennsylvania, Philadelphia, presented key principles of diagnosis and management of spondyloarthritides at the ACR Convergence session CARE: Spondyloarthritis.

You Might Also Like
  • The Big Picture: How to Assess Disease Activity in Patients with axSpA & PsA in Clinical Practice
  • Phase 3 Results for Ixekizumab Promising in Patients with Non-Radiographic Axial Spondyloarthritis
  • Clinical Pearls: What We Know About Nonradiographic Axial Spondyloarthritis
Explore This Issue
January 2022
Also By This Author
  • Targeted Vertebral Fracture Assessment

Psoriatic Arthritis

Dr. Ogdie

Dr. Alexis Ogdie

Dr. Ogdie began her presentation with an overview of the treat-to-target approach to psoriatic arthritis (PsA). She described the primary target as remission and the alternate target as low disease activity. The treat-to-target approach requires that rheumatologists objectively monitor disease, modify treatment to get to target and follow up on any changes in disease activity the patient experiences. This process should be guided by the 2018 ACR/National Psoriasis Foundation Guideline for the Treatment for Psoriatic Arthritis.1

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Although the guideline states that the treat-to-target recommendation for patients with active PsA is conditional based on low-quality evidence, it nevertheless recommends following a treat-to-target strategy for most patients. The guideline does acknowledge, however, that such a strategy may not be appropriate for patients due to the risk of increased adverse events, costs of therapy and the burden imposed by medications and additional visits associated with tighter control.

The guideline recommends that the Disease Activity in Psoriatic Arthritis (DAPSA) or Minimal Disease Activity (MDA) score be used to assess treatment response. DAPSA includes a 68 tender joint count, 66 swollen joint count, patient global assessment of 0–10, patient pain of 0–10 and C-reactive protein (CRP) in mg/dL.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Dr. Ogdie pointed out that if the MDA is used to assess disease activity in patients with PsA, it should include assessment of swollen joints, tender joints, enthesitis, the Health Assessment Questionnaire (HAQ), patient global assessment, patient pain and psoriasis. A paper published after the guideline was released indicated that the Psoriatic Arthritis Impact of Disease (PsAID) questionnaire may be able to replace the HAQ, and, according to Dr. Ogdie, the PsAID is increasingly used by rheumatologists in Europe.2

The 2018 guideline also specifies that, in most cases, a treatment-naive patient with PsA should be prescribed tumor necrosis factor (TNF) inhibitors in preference to oral, small-molecule drugs. Other therapies may be used in special conditions (e.g., an interleukin 17 inhibitor in the setting of severe psoriasis).

Prior to treatment, however, it is important to ascertain if the patient has inflammatory bowel disease, said Dr. Ogdie. If the patient does have inflammatory bowel disease, rheumatologists should not prescribe drugs that are incompatible with the condition, and she emphasized the importance of heeding Boxed Warnings.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

Pages: 1 2 3 | Single Page

Filed Under: ACR Convergence, Conditions, Meeting Reports, Spondyloarthritis Tagged With: ACR Convergence 2021, AS Resource Center, axial spondyloarthritis (SpA), non-radiographic axial spondyloarthritis, Psoriatic ArthritisIssue: January 2022

You Might Also Like:
  • The Big Picture: How to Assess Disease Activity in Patients with axSpA & PsA in Clinical Practice
  • Phase 3 Results for Ixekizumab Promising in Patients with Non-Radiographic Axial Spondyloarthritis
  • Clinical Pearls: What We Know About Nonradiographic Axial Spondyloarthritis
  • New Guideline: NSAIDs Effective in Treating Ankylosing Spondylitis & Nonradiographic Axial Spondyloarthritis

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)